Spinal Restoration
Total Raised
$25MInvestors Count
5Deal Terms
1Spinal Restoration Funding, Spinal Restoration Valuation & Spinal Restoration Revenue
5 Fundings
Spinal Restoration's latest funding round was a Series E for on June 7, 2013.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
---|---|---|---|---|---|---|
6/7/2013 | Series E | Undisclosed Investors | ||||
10/22/2012 | Line of Credit | |||||
10/22/2012 | Series D | |||||
3/17/2010 | Series C | |||||
10/12/2007 | Series B |
Date | 6/7/2013 | 10/22/2012 | 10/22/2012 | 3/17/2010 | 10/12/2007 |
---|---|---|---|---|---|
Round | Series E | Line of Credit | Series D | Series C | Series B |
Amount | |||||
Investors | Undisclosed Investors | ||||
Valuation | |||||
Revenue | |||||
Sources |
Spinal Restoration Deal Terms
1 Deal Term
Spinal Restoration's deal structure is available for 1 funding round, including their Series B from October 12, 2007.
Round | Series B |
---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B |
Spinal Restoration Investors
5 Investors
Spinal Restoration has 5 investors. Austin Ventures invested in Spinal Restoration's Series D funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
---|---|---|---|---|---|---|
10/12/2007 | 10/22/2012 | 3 Series B, Series C (2010), Series D (2012) | Venture Capital | Texas | ||
Venture Capital | Texas | |||||
Venture Capital | Tennessee | |||||
Bank | Texas | |||||
Venture Capital | Texas |
First funding | 10/12/2007 | ||||
---|---|---|---|---|---|
Last Funding | 10/22/2012 | ||||
Investor | |||||
Rounds | 3 Series B, Series C (2010), Series D (2012) | ||||
Board Seats | |||||
Type | Venture Capital | Venture Capital | Venture Capital | Bank | Venture Capital |
Location | Texas | Texas | Tennessee | Texas | Texas |
You May Also Like
Disc Dynamics has developed the DASCORTM Disc Arthroplasty System, an innovative, minimally invasive nucleus replacement treatment for patients suffering from chronic low back pain caused by Degenerative Disc Disease (DDD).

MicroTransponder develops a wireless neurostimulation system for the treatment of chronic pain and several other neurological indications. The minimally invasive device will provide relief from chronic pain without requiring an implanted battery or wires. The Company is finishing R&D on the device and accumulating data toward FDA clearance. MicroTransponder is also adapting the company's system for Vagus Nerve Stimulation to create a pipeline of treatments for other neurological indications, including stroke rehabilitation, tinnitus, and autism.
Axial Biotech, founded in 2002 by a group of spine surgeons and geneticists, is focused on the use of genetics and the development of minimally invasive fusionless devices to advance the diagnosis and treatment of diseases and deformities of the human spine. Axial is a company to pursue DNA-based pre-symptomatic and prognostic tests for common spinal conditions which will augment current clinical and surgical practices. In its initial genetic product development initiative, Axial has made progress towards the discovery of a location in the human genome that is associated with adolescent idiopathic scoliosis. In addition, Axial's founders have developed five motion preserving, fusionless surgical devices (including such device currently being implanted in humans) that have the promise of expanding the current treatable scoliosis patient population by a factor of ten. Axial intends to use its genetic intellectual property in the development of bio-mechanical devices, and to apply its gene discovery/product development methodology to other spinal diseases. Axial (www.axialbiotech.com) is located in Salt Lake City, Utah.
BioSpiral's state-of-art system aims to provide prostate cancer treatment as a minimally invasive procedure, which uses cooling & heating technologies to destroy prostate cancer.nBioSpiral was established in Sep 2006 and is operating as part of NGT Incubator. nBioSpiral prostate thermodynamics therapy is an effective, minimally invasive treatment for prostate cancer that does not involve the difficulty and complications associated with surgery, nor the harmful properties of radiation or cryotherapy .The system revolutionizes prostate cancer treatment by introducing a "one shot" treatment method under local anesthesia at the physician's clinic. BioSpiral treatment is for patients with localized prostate cancer, who look for an effective minimal invasive therapy for prostate cancer. Additionally, this treatment can also be used by patients who have local recurrence after other treatments ("salvage" treatment). Key advantages:nCost effective: short treatment, no need for O.R or hospitalizationnHighly efficient: tissue ablationnPatients: high quality of life; minimal side effects, minimal invasive, short treatment & recovery.
Simpirica is developing a dynamic stabilization system designed to stabilize the spine in flexion and help patients return to more healthy, active lifestyles. The company's lead product, the LimiFlex Spinal Stabilization System, is typically used in conjunction with a surgical decompression for the treatment of lumbar spinal stenosis with or without degenerative spondylolisthesis.

Spine Wave is developing a procedure for treating back pain and other spinal conditions by restoring the function of the spinal disc. The procedure uses an injectable protein-based formulation for the repair of spinal discs damaged either by injury or aging.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.